Immuneering annual return on equity
2021
2022
2023
2024
2025
Immuneering Return on Equity (ROE) Growth & History (IMRX)
Immuneering's return on equity was −43.12% for fiscal 2025.
View full Immuneering company overviewImmuneering annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −43.12% | +49.39 pp |
| 2024 | 2024-12-31 | −92.51% | −39.15 pp |
| 2023 | 2023-12-31 | −53.36% | −15.35 pp |
| 2022 | 2022-12-31 | −38.00% | +12.24 pp |
| 2021 | 2021-12-31 | −50.24% | — |
Immuneering quarterly return on equity
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −8.69% | +32.09 pp |
| Q1 2026 | 2026-03-31 | −6.33% | +29.82 pp |
| Q4 2025 | 2025-12-31 | −5.19% | +31.24 pp |
| Q3 2025 | 2025-09-30 | −11.65% | +11.89 pp |
| Q2 2025 | 2025-06-30 | −40.79% | −21.37 pp |
| Q1 2025 | 2025-03-31 | −36.16% | −19.25 pp |
| Q4 2024 | 2024-12-31 | −36.43% | −20.93 pp |
| Q3 2024 | 2024-09-30 | −23.54% | −12.04 pp |
| Q2 2024 | 2024-06-30 | −19.42% | −7.97 pp |
| Q1 2024 | 2024-03-31 | −16.90% | −3.80 pp |
| Q4 2023 | 2023-12-31 | −15.50% | −4.07 pp |
| Q3 2023 | 2023-09-30 | −11.50% | −1.44 pp |
| Q2 2023 | 2023-06-30 | −11.45% | −3.15 pp |
| Q1 2023 | 2023-03-31 | −13.10% | −4.51 pp |
| Q4 2022 | 2022-12-31 | −11.43% | −4.57 pp |
| Q3 2022 | 2022-09-30 | −10.05% | +3.81 pp |
| Q2 2022 | 2022-06-30 | −8.30% | — |
| Q1 2022 | 2022-03-31 | −8.60% | — |
| Q4 2021 | 2021-12-31 | −6.86% | — |
| Q3 2021 | 2021-09-30 | −13.86% | — |
Immuneering return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Immuneering's return on equity increased from −50.24% to −43.12%, a change of +7.12 percentage points. The latest reported quarter, Q2 2026, shows −8.69%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immuneering source filings ↗